Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients

Purde, Mette‑Triin; Niederer, Rebekka; Wagner, ikolaus B.; Diem, Stefan; Berner, Fiamma; Hasan Ali, Omar; Hillmann, Dorothea; Bergamin, Irina; Joerger, Markus; Risch, Martin; Niederhauser, Christoph; Lenz, Tobias L.; Früh, Martin; Risch, Lorenz; Semela, David; Flatz, Lukas (2022). Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. Journal of cancer research and clinical oncology, 148(3), pp. 647-656. Springer 10.1007/s00432-021-03870-6

[img]
Preview
Text
Purde2021_Article_PresenceOfAutoantibodiesInSeru.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Abstract
Purpose: Immune checkpoint inhibitor (ICI)-induced hepatitis belongs to the frequently occurring immune-related adverse events (irAEs), particularly with the combination therapy involving ipilimumab and nivolumab. However, predisposing factors predicting the occurrence of ICI-induced hepatitis are barely known. We investigated the association of preexisting autoantibodies in the development of ICI-induced hepatitis in a prospective cohort of cancer patients.

Methods: Data from a prospective biomarker cohort comprising melanoma and non-small cell lung cancer (NSCLC) patients were used to analyze the incidence of ICI-induced hepatitis, putatively associated factors, and outcome.

Results: 40 patients with melanoma and 91 patients with NSCLC received ICI between July 2016 and May 2019. 11 patients developed ICI-induced hepatitis (8.4%). Prior to treatment, 45.5% of patients in the hepatitis cohort and 43.8% of the control cohort showed elevated titers of autoantibodies commonly associated with autoimmune liver diseases (p = 0.82). We found two nominally significant associations between the occurrence of ICI-induced hepatitis and HLA alleles associated with autoimmune liver diseases among NSCLC patients. Of note, significantly more patients with ICI-induced hepatitis developed additional irAEs in other organs (p = 0.0001). Neither overall nor progression-free survival was affected in the hepatitis group.

Conclusion: We found nominally significant associations of ICI-induced hepatitis with two HLA alleles. ICI-induced hepatitis showed no correlation with liver-specific autoantibodies, but frequently co-occurred with irAEs affecting other organs. Unlike other irAEs, ICI-induced hepatitis is not associated with a better prognosis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases > Research
04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

UniBE Contributor:

Niederhauser-Lüthi, Christoph Peter, Früh, Martin

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

1432-1335

Publisher:

Springer

Language:

English

Submitter:

Christoph Peter Niederhauser-Lüthi

Date Deposited:

16 Dec 2021 12:30

Last Modified:

12 Dec 2022 18:38

Publisher DOI:

10.1007/s00432-021-03870-6

PubMed ID:

34874490

BORIS DOI:

10.48350/162047

URI:

https://boris.unibe.ch/id/eprint/162047

Actions (login required)

Edit item Edit item
Provide Feedback